Treatment of Gout: Reflections From the GEMA Study;Tratamiento de la gota: reflexiones desde el estudio GEMA

Reumatologia Clinica

Volumn 4, Issue SUPPL. 2, 2008, Pages 41-44

  Pérez Ruiz, Fernando ^a  

^a HOSPITAL DE CRUCES   (Spain)

Author keywords

Audit; Diagnosis; Gout; Treatment

Indexed keywords

EID: 63649099711     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/S1699-258X(08)76167-9     Document Type: Article

References (18)

1. Schlesinger N., Moore D.F., Sun J.D., and Schumacher Jr. H.R. A survey of current evaluation and treatment of gout. J Rheumatol 33 (2006) 2050-2052
2. Zhang W., Doherty M., Pascual E., Bardin T., Barskova V., Conagham P., et al. EULAR evidence based recommendations for gout Part I. Diagnosis. Report of a Task Force of the EULAR Standing Committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 65 (2006) 1301-1311
3. Zhang W., Doherty M., Bardin T., Pacual E., Barskova V., Conagham P., et al. EULAR evidence based recommendations for gout Part II. Management. Report of a Task Force of the EULAR Standing Committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 65 (2006) 1312-1324
4. Ganson N.J., Kelly S.J., Scarlett E., Sundy J.S., and Hershfield M.S. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene) glycol (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 8 (2005) R12
5. Reinders M.K., Van Roon E.N., Houtman P.M., Brouwers J.R., and Jansen T.L. Biochemical effectiveness of allopurinol and allopurinolprobenecid in previously benzbromarone-treated gout patients. Clin Rheumatol 26 (2007) 1459-1465
6. Reinders MK, Van Roon EN, Jansen TL, Delsing J, Griep EN, Hoekstra M, et al. Efficacy and tolerability of urate lowering drugs in gout: a randomized controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2008 [en prensa].
7. Schumacher Jr. H.R., Edwards L.N., Perez-Ruiz F., et al. Outcome measures for acute and chronic gout. J Rheumatol 32 (2005) 2452-2455
8. Schlesinger N. Response to application of ice may help differentiate between gouty arthritis and other inflammatory arthritides. J Clin Rheumatol 12 (2006) 275-276
9. Petersel D., and Schlesinger N. Treatment of acute gout in hospitalized patients. J Rheumatol 34 (2007) 1566-1568
10. Neogi T., Hunter D.J., Chaisson C.E., Allensworth-Davies D., and Zhang Y. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 33 (2006) 104-109
11. Schlesinger N., and Schumacher Jr. H.R. Gout: can management be improved?. Curr Opin Rheumatol 13 (2001) 240-244
12. Bellamy N., Gilbert J.R., Brooks P.M., Emmerson B.T., and Campbell J. A survey of current prescribing practices of antiinflammatory drugs and urate lowering drugs in gouty arthritis in the province of Ontario. J Rheumatol 15 (1988) 1841-1847
13. Roddy E., Zhang W., and Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis 66 (2007) 1311-1315
14. Riedel A.A., Nelson M., Joseph-Ridge N., Wallace K., MacDonald P.A., and Becker M. Compliance with allopurinol therapy among managed care enrollees with gout: A retrospective analysis of administrative claims. J Rheumatol 31 (2006) 1575-1581
15. Becker M.A., Schumacher Jr. H.R., Wortmann R.L., et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353 (2005) 2450-2461
16. Perez-Ruiz F., Alonso-Ruiz A., Calabozo M., Herrero-Beites A., Garcia-Erauskin G., and Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 57 (1998) 545-549
17. Perez-Ruiz F., Calabozo M., Fernandez-Lopez M.J., Herrero-Beites A.M., Ruiz-Lucea E., Garcia-Erauskin G., et al. Treatment of chronic gout in patients with renal function impairment. An open, randomized, actively controlled. J Clin Rheumatol 5 (1999) 49-55
18. Perez-Ruiz F., Calabozo M., Pijoan J.I., Herrero-Beites A.M., and Ruibal A. Effect of urate-lowering therapy on the velocityof size reduction of tophi in chronic gout. Arthritis Rheum 47 (2002) 356-360